离子交换树脂法制备盐酸左西曲嗪掩口溶片及评价

R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu
{"title":"离子交换树脂法制备盐酸左西曲嗪掩口溶片及评价","authors":"R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu","doi":"10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109","DOIUrl":null,"url":null,"abstract":"http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.","PeriodicalId":14211,"journal":{"name":"International Journal of Research and Development in Pharmacy & Life Sciences","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Formulation and evaluation of Taste Masked Mouth Dissolving Tablet of Levocetrizine dihydrochloride by using Ion-Exchange Resin\",\"authors\":\"R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu\",\"doi\":\"10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.\",\"PeriodicalId\":14211,\"journal\":{\"name\":\"International Journal of Research and Development in Pharmacy & Life Sciences\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Research and Development in Pharmacy & Life Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research and Development in Pharmacy & Life Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109摘要:盐酸左西替利嗪是由第二代抗组胺药头孢嗪衍生而来的第三代非镇静性抗组胺药。它是h1受体拮抗剂。变应性鼻炎是过敏原暴露后,由鼻粘膜免疫球蛋白(IgE)介导的炎症引起的鼻部症状性疾病。因此,将左西替利嗪配制成可分散的剂型将提供快速缓解。左西替利嗪的味道是苦的,所以Kyron T-134(离子交换树脂合成物是惰性有机聚合物,由碳氢化合物网络组成,可电离基团附着在碳氢化合物网络上,它们有能力将不稳定的离子交换为与它们接触的溶液中的离子)被用来掩盖味道,并使用药物树脂复合物配制口腔溶解片。对其进行药物含量、重量变化、吸水率、润湿时间、体外崩解、硬度、脆度、厚度等评价。所有参数均在可接受范围内。优化后的处方在25秒内崩解,10分钟内完全释药。与市售制剂进行了比较,发现其药物释放率有所提高。结果表明,盐酸左西替利嗪可成功配制成口腔溶出片。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Formulation and evaluation of Taste Masked Mouth Dissolving Tablet of Levocetrizine dihydrochloride by using Ion-Exchange Resin
http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信